An in vitro and in vivo study of antitumor effects of genistein on hormone refractory prostate cancer

Anticancer Res. Nov-Dec 1994;14(6B):2617-9.

Abstract

Hormone refractory prostate cancer remains an incurable disease. Newer agents with more activity are required. Genistein is a flavone compound with anti-tumor activity against various tumor systems in vitro. This study is undertaken to assess the efficacy of genistein against hormone refractory prostate cancer. In vitro, genistein appears to be cytotoxic to both the rat prostate cancer cell line MAT-LyLu and the human prostate adenocarcinoma cell line, PC-3. In vivo, however, genistein failed to significantly inhibit the growth of subcutaneously implanted MAT-LyLu cells. More information regarding the pharmacokinetics and bio-availability of genistein is needed to determine if this is an active agent in human metastatic prostate cancer.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / pathology
  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Agents / toxicity
  • Cell Division / drug effects
  • Cell Line
  • Cell Survival / drug effects
  • Dose-Response Relationship, Drug
  • Genistein
  • Humans
  • Isoflavones / therapeutic use*
  • Isoflavones / toxicity*
  • Male
  • Neoplasm Metastasis
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / pathology
  • Rats
  • Rats, Inbred Strains
  • Tumor Cells, Cultured

Substances

  • Antineoplastic Agents
  • Isoflavones
  • Genistein